UNSPSC 51401526: Flunitrazepam

This classification denotes a benzodiazepine with the molecular formula C16H12FN3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 620X0222FQ, chemically known as 1,3-dihydro-5-(o-fluorophenyl)-1-methyl-7-nitro-2h-1,4-benzodiazepin-2-one but generally known as flunitrazepam, which bears US NIH Compound Identifier 3380. European Medicines Agency schedules Flunitrazepam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07710MIG.

UNSPSC 51401526 Flunitrazepam is a Commodity code that does not align with the recent state and local procurement activity tagged under it. Flunitrazepam is a controlled substance (benzodiazepine) subject to strict regulatory scheduling and dispensing controls; the recent solicitations under this code, however, cover naloxone procurement, therapeutic pharmacy initiatives, and generic multi-source pharmaceuticals — none of which involve flunitrazepam or controlled substances in the manner the code nominally describes. The mismatch between the code's scope and the actual work being solicited suggests either a tagging error or a systematic misclassification in the source data. State and local agencies issuing under this code show no evidence of purchasing flunitrazepam itself.

The three recent opportunities reflect pharmaceutical supply chain and community health procurement across different issuing bodies and geographies. Seminole County, Florida issued IFB 60459723LAS in June 2026 (due July 26, 2026) to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries, with E-Verify compliance and E-procurement portal submission required. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather market intelligence on direct-to-manufacturer prescription programs and vendor capabilities for self-insured pharmacy benefit models. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 in January 2026 (responses due March 26, 2026) to establish multi-award contracts for generic pharmaceuticals and OTC products distributed through three authorized wholesalers to state and local government facilities in Minnesota and Oregon, with evaluation weighted 75 percent on price competitiveness, 10 percent on fixed pricing, and 5 percent each on administrative fee compliance, EDI capability, and format requirements. These opportunities span state health agencies, county public health operations, and cooperative purchasing vehicles, with activity concentrated in Florida, Texas, and the Upper Midwest as of mid-2026.